Objective: To compare visual acuity at 6 years of age in eyes that received early treatment for high-risk prethreshold retinopathy of prematurity (ROP) with conventionally managed eyes.
T HE MULTICENTER TRIAL OF Cryotherapy for Retinopathy of Prematurity Study (CRYO-ROP) evaluated the effectiveness of peripheral retinal ablation at threshold disease (Figure 1) for the treatment of retinopathy of prematurity (ROP), 2, 3 using the International Classification for Retinopathy of Prematurity (ICROP). 4 The CRYO-ROP Study defined prethreshold ROP ( Figure 1 ) to help identify infants' eyes at risk for progression to threshold. Cryotherapy reduced the rate of adverse outcome in threshold ROP by approximately 50%, but many important questions remained about the disease and its treatment. 5 The Early Treatment for Retinopathy of Prematurity (ETROP) Study was designed to test the hypothesis that early treatment in high-risk prethreshold eyes would further improve visual acuity outcomes 6 measured with the Teller acuity card procedure 7, 8 at 9 months' corrected age. 9 High risk was determined by an equation derived from analyses of CRYO-ROP data that took into account a number of risk factors. 1 If an infant with prethreshold ROP had a risk for progression to an unfavorable outcome equal to or greater than 15%, randomization was offered, with one eye treated early and the other followed and managed conventionally (RM-ROP2).
1 Conventional management consisted of treatment at threshold (Figure 1 ) or observation until the ROP regressed without needing treatment. In infants with only one eye eligible, the high-risk prethreshold eye was randomized to early treatment or conventional management.
The ETROP Study showed a benefit for 9-month grating acuity for eyes with high- risk prethreshold ROP treated with peripheral retinal ablation. 9 A retinal structural outcome benefit was also noted for eyes receiving early treatment. This structural benefit of early treatment was shown to persist to at least 2 years of age. 10 Recognizing that use of the risk model algorithm to determine indications for treatment might not always be practical in an intensive care nursery setting, the ETROP Cooperative Group also analyzed results based only on the ocular changes of ROP. Importantly, these analyses resulted in a clinical algorithm wherein Type 1 and Type 2 prethreshold disease emerged as indications for treatment or cautious observation, respectively. Type 1 eyes are those with plus disease in either Zone I or Zone II, or Zone I stage 3 disease. 9 Type 2 eyes are all other eyes with prethreshold disease, whether high risk or not ( Figure 1 ). Plus disease was defined as dilation and tortuosity of posterior retinal vessels in at least two quadrants as compared with a standard published picture (Figure 2 ). Clinical use of the Type 1 and Type 2 categories may decrease treatment of eyes that would undergo regression of ROP without requiring retinal ablation.
Type 1 prethreshold ROP is not identical to high-risk prethreshold ROP, nor is Type 2 synonymous with lowrisk prethreshold ROP. These categories, Types 1 and 2, were developed based on all prethreshold eyes (not only high-risk prethreshold eyes) in the ETROP Study to learn whether anatomical features defined in ICROP could be used by practicing ophthalmologists at the cribside to determine whether an infant's eye or eyes would benefit from treatment. The ETROP Study recommended that Type 1 eyes should be treated promptly, while Type 2 eyes could be watched carefully and treated if the ROP progressed to Type 1. The difference between Type 1 and Type 2 vs lowrisk and high-risk prethreshold eyes is developed fully in a previous publication. 9 Many questions about the effect of early treatment of eyes were raised after publication of the ETROP 9-month visual acuity outcomes article. Would the benefit to visual acuity for early-treated eyes seen at 9 months persist to age 6 years, and what would be the long-term effect of extensive retinal ablation on visual field extent? Would Type 1 and Type 2 diagnoses remain useful? This article presents the visual acuity and structural findings at 6 years of age for children who were randomized into the ETROP Study in the perinatal period.
METHODS
Study protocols were approved by the review boards of all participating institutions, and parents provided written informed consent for participation in the extended follow-up study to allow vision measurements on a yearly basis through 6 years of age.
A total of 401 infants were randomized between October 1, 2000, and September 30, 2002 . Three hundred seventy of these children survived until 6 years of age ( Figure 3A) . Details of the design of the ETROP Study, and of the model used to calculate whether an infant was at high or low risk, have been previously published. 1, 11 Randomized infants had either symmetrical, high-risk prethreshold disease, in which case one eye was randomized to early treatment and the other to conventional management, or they had one eye with high-risk prethreshold disease, which was randomized to either early treatment or conventional management.
VISUAL ACUITY ASSESSMENT
Recognition (letter) visual acuity was assessed with the ETDRS charts 12 (Precision Vision, Inc, LaSalle, Illinois) in all children whose developmental skills allowed the measurement. Children were excluded from the visual acuity examination if both a certified examiner and parent agreed that both eyes had only light perception (LP) or worse vision and the child had bilateral retinal detachments, phthisis bulbi, or bilateral enucleations.
Testing was conducted by a masked, traveling tester who was unaware of the child's treatment assignment. The testing location was a comfortable, quiet room, and luminance of the ETDRS chart was at least 10 cd/m 2 . All children underwent cycloplegic refraction within 3 months of the final 6-year acuity assessment. Glasses were required for myopia in an eye of 1.00 diopter (D) or more; hyperopia, 4.00 D or more; or astigmatism, 1.50 D or more. In the case of amblyopia as judged by the examining ophthalmologist, glasses were required for anisometropia of 1.50 D or more spherical equivalent or cylinder. Cycloplegic refraction was performed immediately after visual acuity testing. If it was determined that the child's refraction was not corrected to within these limits, the acuity test was re- peated with the proper prescription. Because each child underwent yearly eye examinations as part of the study, amblyopia, strabismus, and refractive errors were managed prior to the 6-year examination. The procedure used for assessment of recognition acuity consisted of 3 steps: training, screening, and testing. The training and screening steps were conducted binocularly, and the testing step was conducted monocularly, with the right eye tested first. In the training step, the child was taught about the test by parents, who were sent sample acuity letters by mail preceding the final visit. The child was also given instructions by the tester at the time of the acuity test. Next, the tester screened the child for the ability to take the test by showing large, individual copies of the 10 letters on the test at a distance of approximately 1 m to determine whether the child could identify each letter by naming or by matching to letters on a lap card. A child continued to the acuity testing step only if he or she correctly identified or matched 9 of 10 consecutive letters. If a child could not name or match the letters because of developmental or cognitive reasons, then testing with an HOTV chart was attempted. HOTV testing was not performed on all children. Those who could only perform the HOTV task or whose score on developmental assessment indicated moderately delayed cognitive status were scheduled for a second visual acuity test 6 to 12 months later.
The visual acuity test was performed as follows. The child was seated comfortably, wearing glasses or trial frames if needed to correct refractive error. The left eye was covered with an adhesive eye patch. Test distance was 4 m but was reduced to 1 m or to 0.5 m if needed to permit letter identification in an eye with poor vision. The child read from the top line down, until he or she missed 3 letters on a line. The line above this was scored as the visual acuity threshold for that eye, with appropriate adjustment for the chart distance. The tester moved the patch to the right eye and, using a different ETDRS chart, measured acuity in the left eye.
Visual acuity results were categorized as normal (20/40 or better visual acuity), below normal (worse than 20/40 to better than 20/200), poor (measurable acuity of 20/200 or worse), or blind/low vision (only the ability to detect the 2.2-cm wide stripes on the low-vision Teller acuity card at any distance and at any location in the visual field, LP only, or no LP). Acuity results in the normal and below-normal categories were classified as favorable outcomes, and acuity results in the poor and blind/low-vision categories were classified as unfavorable outcomes.
Monocular grating acuity was measured for all children using the Teller acuity card procedure. 7, 8 These results will be presented in future communications.
SECONDARY ASSESSMENTS
Structural outcome was evaluated through a complete ophthalmological examination, including cycloplegic refraction following instillation of cyclopentolate, 1%. When there was a medical contraindication to using cyclopentolate, 1%, cyclopentolate, 0.5%, or tropicamide, 1%, was used. The examination was conducted by a study-certified ophthalmologist who was not formally masked to the eye's treatment assignment but was asked to refrain from seeking information and did not have access to visual acuity data until after completing the examination forms. An unfavorable retinal structural outcome was defined as follows: (1) a posterior retinal fold involving the macula, (2) a retinal detachment involving the macula, (3) retrolental tissue or mass obscuring the view of the posterior pole, and (4) a vitrectomy or scleral buckling procedure.
A questionnaire assessing the child's functional level was administered to the parents at the time of the 6-year evaluation by a trained individual (WeeFIM 13 ). Children were tested for visual field extent and contrast sensitivity. 14, 15 Results of these examinations will be forthcoming in separate publications.
DATA AND SAFETY MONITORING COMMITTEE
A Data and Safety Monitoring Committee of biostatisticians, pediatric ophthalmologists, an ethicist, and a neonatologist, not directly involved with the study, met annually to review ad- verse events and monitor the progress of the study. The committee approved any protocol changes and monitored the performance of participating centers. Manuscripts for the study were also reviewed by the committee prior to submission for publication.
STATISTICAL METHODS
The statistical method that was developed for use in the CRYO-ROP Study 16 was used for analysis of ETROP results. The method is an adaptation of the Mantel-Haenszel 2 procedure for matched-pairs data for children with symmetric disease that allows data from these children to be combined with data from children with asymmetric disease.
A further analysis was done comparing the full range of acuity using Wilcoxon nonparametric rank tests. For the symmetric eyes, an estimator of the treatment effect was computed using the Hodges-Lehmann estimator associated with the Wilcoxon signed rank test. 17 Similarly, for the asymmetric eyes, an estimator of the treatment effect was computed using the HodgesLehmann estimator associated with the two-sample Wilcoxon rank sum test. A combined estimator of the treatment effect was computed by taking a weighted average of the two estimates of the treatment effect with weights proportional to the reciprocal of the variances of the estimators. In essence, this is equivalent to a meta-analysis combining estimates of the treatment effect for symmetric eyes with asymmetric eyes. Also, an interaction test was done using a z test comparing the difference in treatment effects for Type 1 eyes vs Type 2 eyes. The z value was computed by dividing the difference in the treatment effects by the square root of the sum of the variance in the two treatment effects. Figure 3B shows the protocol for all prethreshold eyes. Figure 3A shows the final disposition of the 401 ETROP study participants. At the final 6-year examination, 342 (92.4%) of the surviving 370 children were examined, 271 children with symmetrical disease and 71 children with asymmetrical disease. Eighteen children with moderate developmental delays could not perform the ETDRS test at the initial outcome assessment visit and were asked to return for subsequent testing. Thirteen children returned for retesting, of whom 10 were able to perform ETDRS testing. Their data are included in the primary outcome analysis. Of the 3 who could not provide ETDRS data, only one could be tested with the HOTV test. That child's data are not included in the visual acuity data analysis. Table 1 presents the proportion of randomized eyes with unfavorable ETDRS acuity at 6 years of age. Overall, the data do not demonstrate a statistically significant benefit for early treatment, with 24.6% of earlytreated high-risk prethreshold eyes and 29.0% of conventionally managed eyes having unfavorable outcomes (P=.15). Within-subject comparisons of the children with bilateral disease showed that there were 33 children with favorable outcomes in their early-treated eyes and unfavorable outcomes in their conventionally managed eyes (discordant pairs), and 24 children had unfavorable outcomes in early-treated eyes and favorable outcomes in conventionally managed eyes. This difference was not statistically significant (P=.23). Table 2 provides the distribution of 6-year ETDRS acuity outcomes among randomized eyes by treatment assignment and visual acuity category. No data are shown for the 27 of the 307 early-treated eyes and the 23 of the 299 conventionally managed eyes that could not be tested with the ETDRS charts. The ETDRS acuity data were analyzed comparing the two treatments using rank tests that controlled for whether a child had bilateral disease or asymmetric disease. The overall rank test for the shift in acuity distribution indicated a P value of .02. This nonparametric approach shows a slightly higher number of eyes that are in the 20/60 or better categories for earlytreated eyes and at the same time slightly more eyes that are in the poorest category (blind/low vision) for conventionally managed eyes (Figure 4) .
RESULTS
Analysis of the ETDRS acuity data using Type 1 and Type 2 groupings as proposed in the 2003 ETROP results publication is shown in Table 3 for eyes that were high risk based on the RM-ROP2 algorithm.
1 Analysis using this clinical algorithm showed that Type 1 eyes had a 25.1% unfavorable outcome rate when treated early, while conventionally managed Type 1 eyes had a 32.8% unfavorable outcome (PϽ.001). By contrast, Type 2 eyes that were high risk per the RM-ROP2 algorithm showed no significant difference, with a slightly higher unfavorable outcome rate for the early-treated eyes of 23.6% vs 19.4% for conventionally managed eyes (P = .18). Table 4 presents subgroups of ETDRS acuity outcome at 6 years for children with bilateral high-risk prethreshold ROP by ICROP category, RM-ROP2 risk, and Type 1/Type 2 disease. The greatest benefit for early treatment was seen in eyes with Zone I, stage 3 disease with or without plus disease. The benefit of early treatment also increased with increasing risk and was most pronounced in children with 45% or more risk for unfavorable outcome. When data were analyzed by Type 1 or Type 2 status, a significant benefit to early treatment for eyes with Type 1 disease was seen, but not for eyes with Type 2 disease.
For the secondary outcome, retinal structure, the difference in unfavorable outcomes for all high-risk prethreshold eyes was 8.9% for early-treated eyes vs 15.2% for conventionally managed eyes ( Table 5 ) (PϽ.001). Data for children with symmetrical high-risk prethreshold disease showed that 10.0% of the early-treated eyes vs 16.6% of the conventionally managed eyes had unfavorable structural outcomes. Of children with symmetrical disease, 23 had favorable outcomes in early-treated eyes and unfavorable outcomes in conventionally managed eyes. Six children had unfavorable outcomes in early-treated and favorable outcomes in conventionally managed eyes. Table 6 presents subgroups of retinal structure outcomes at 6 years for children with bilateral high-risk prethreshold ROP by ICROP category, RM-ROP2 risk, and Type 1/Type 2 disease. As with visual acuity (Table 4) , the greatest benefit for early treatment was seen in eyes with Zone I, stage 3 disease with or without plus disease, with a doubling of unfavorable outcomes in the conventionally managed eyes. There was also benefit for early treatment for Zone II, stage 3 disease with plus disease. The benefit of early treatment also increased with increasing risk and was most pronounced in children with 45% or more risk for unfavorable outcome. When data were analyzed by Type 1 or Type 2 status, a striking benefit to early treatment for eyes with Type 1 disease was seen, but not for eyes with Type 2 disease. b Less than 271 because of inability to determine the structural outcome. c Based on discordant pairs (23 children with favorable outcomes in early-treated eyes and unfavorable outcomes in conventionally managed eyes; 6 children with unfavorable outcomes in early-treated eyes and favorable outcomes in conventionally managed eyes).
d Less than 39 because of inability to determine the structural outcome.
gressed and later underwent treatment at threshold ROP or underwent involution of ROP without requiring treatment. Ocular complication rates were similar in the two groups, though more conventionally managed than early-treated eyes had unsteady fixation or retinal detachment. Cataract or aphakia was found in 4.9% of early-treated eyes and in 7.2% of conventionally managed eyes. With regard to mortality in the ETROP follow-up cohort, 31 randomized children died before the 6-year examination, but none of the deaths was related to ophthalmology care.
COMMENT
The ETROP Study was conducted on eyes that were high risk using the RM-ROP2 risk model. However, with a desire to have a clinical algorithm that could be conveniently applied, the evaluation of initial outcome data collected when study participants were 9 months' corrected age included an analysis of results on the basis of standard ROP characteristics. 9 The analysis identified eyes with characteristics indicating a benefit for early treatment (Type 1) and eyes that could be observed (Type 2), with treatment offered if the disease progressed to Type 1. These divisions into Type 1 and Type 2 eyes were not preplanned as part of the original design in 1999 but came about in 2003 as a result of analysis of initial study outcome data. There was an obligation to follow these eyes according to this subdivision once the types had been developed and published.
As indicated in the present report, the importance of the difference between eyes with Type 1 vs Type 2 ROP is emphasized by the results of visual acuity assessment at age 6 years. Based on the predefined primary analysis, no statistically significant benefit at the 5% level was seen from early treatment compared with conventional management of high-risk prethreshold eyes when results were analyzed for all subjects who had high-risk prethreshold Abbreviations: ICROP, International Classification for Retinopathy of Prematurity; RM-ROP2, risk management of ROP for prethreshold eyes; S, stage; Z, Zone; ϩ, with plus disease; −, without plus disease.
a Data are presented as number (percentage unfavorable) unless otherwise indicated.
b For group A, early-treated eyes had a favorable outcome and conventionally managed eyes had an unfavorable outcome.
c For group B, early-treated eyes had an unfavorable outcome and conventionally managed eyes had a favorable outcome. ROP, the criterion for entry into the study (risk Ն0.15) . However, when the 6-year visual acuity results were analyzed using the ETROP-developed clinical algorithms Type 1 and Type 2, a benefit was seen for Type 1 eyes (P=.02) that were treated early but not for early-treated Type 2 eyes (Table 3) .
When one analyzes the ETDRS data as continuous rather than categorical (favorable vs unfavorable) data, the results for Type 1 and Type 2 clearly show different outcomes (Type 1 eyes, PϽ.001; Type 2 eyes, P=.18) , and analysis of an interaction effect showed that differences between treatment for Type 1 eyes vs Type 2 eyes were highly significant (P=.006). Results presented in 2003 calling for watchful waiting for Type 2 eyes are even more important given the ETDRS acuity results at age 6 years, because data on structural outcome at 6 months' corrected age indicated that 77.3% of low-and high-risk Type 2 eyes regress, whereas 31.5% of Type 1 eyes (whether low-or high-risk prethreshold eyes) regress. 9 Retinal structural outcome continues to show a benefit from early treatment. This benefit was noted at 6 and 9 months' corrected age and at 2 years' postnatal age 10 and has persisted to the 6-year outcome examination. Structural benefit exceeds visual acuity outcome benefit in the 6-year examination, just as it did at the 9-month examination 9 and as it did in the CRYO-ROP Study. 5 There are a number of reasons for this, including the possibility that ROP per se somehow affects visual acuity or that central nervous system changes related to preterm birth are partially responsible for reduction in visual acuity. 18 While immaturity of the visual system at 9 months of age could have accounted for this discrepancy, by 6 years the visual system is nearly mature.
The findings of the present report are strengthened because of the high follow-up rate (Ͼ92%); certification and training of the ophthalmologists who performed the examinations on which characterization of ROP and the randomization of study participants were based; the certification and training of the ophthalmologists who performed study outcome examinations; and the training, certification, and masking of the visual acuity testers. The potential diagnostic uncertainty of plus disease, a characteristic that carries considerable importance in distinguishing Type 1 from Type 2 prethreshold ROP, may represent a limitation. To minimize this potential uncertainty, the study used confirming examinations by masked, certified examiners prior to randomization, the group of investigators held regular meetings to review criteria for plus disease, and site visits to examine infants at each of the centers were used to calibrate studycertified ophthalmologists.
The CRYO-ROP Study showed a benefit for treatment at threshold ROP (Figure 1) . However, visual acuity outcome measures indicated that many children still had acuity of 20/200 or worse. In the 10-year follow-up examination, the rate of unfavorable visual acuity outcome (20/200 or worse) after cryotherapy was 44.4% for treated eyes and 62.1% for control (untreated) eyes. 19 At the 15-year follow-up examination, the distribution of unfavorable visual acuity outcomes was 44.7% in treated eyes vs 64.3% in control eyes. 20 One of the motivations for testing whether early treatment of eyes with ROP of near-threshold severity was to learn whether visual acuity results would improve with this management approach.
In the ETROP Study, when children reached 6 years of age, 24.7% of eyes treated at high-risk prethreshold ROP showed visual acuity of 20/200 or worse vs 29.0% of eyes conventionally managed. When Type 1 eyes were considered, the difference between early treatment and conventional management was 25.1% vs 32.8%. Improvement was noted for eyes with Type 1 ROP only, with Type 2 eyes showing no benefit. Two-thirds of early-treated eyes still showed visual acuity worse than 20/40. Comparisons with data from the CRYO-ROP Study cannot be made because the cohorts of children are very different. In the CRYO-ROP Study, all infants with birth weight less than 1251 g were eligible for randomization if threshold disease developed. In the ETROP Study, infants had to be less than 1251 g, have prethreshold ROP, and have a risk for blindness of 15% or more to be eligible for randomization.
Is there any evidence that treatment for Type 2 ROP could be deleterious to the eye or to the patient? In the ETROP Study, 41.3% of randomized eyes had Zone I disease. While possible reasons for this high percentage have been discussed, 9 these eyes received an extensive amount of peripheral retinal ablation and are at risk for visual field loss. A future manuscript will present and discuss the visual field findings. Data from visual acuity findings indicate that early treatment of eyes at the time of identification of prethreshold disease with Type 2 characteristics is of no benefit (23.6% unfavorable acuity outcome with early treatment vs 19.4% unfavorable with conventional management). Furthermore, there is no benefit from early treatment for Type 2 eyes on analysis of structural outcome (Table 6 ). Additionally, in the previous publication, 9 we noted that 52% of high-risk Type 2 eyes regressed without requiring treatment. Given the possible risks, such as risk for cataract 10 and increased systemic risk for apnea and bradycardia, 9 it would seem prudent to exercise restraint and clinical judgment when deciding whether to operate on Type 2 eyes unless they show signs of further progression.
In conclusion, the final visual acuity examination at 6 years of age in children enrolled in the ETROP Study shows a lasting benefit for early treatment of some eyes with ROP. However, the benefit is present only for eyes with Type 1 disease as defined in this study. Visual acuity is improved with early treatment, but nevertheless, 65.4% of eyes receiving early treatment develop visual acuity worse than 20/40. Whether this result is due to retinal, cortical, or both factors remains to be determined, but clearly prevention of ROP now assumes an even higher priority since early treatment is beneficial for some eyes but often does not result in normal development of visual acuity. October 14, 2009 ; final revision received January 5, 2010; accepted January 21, 2010 . Published Online: April 12, 2010 April 12, (doi:10.1001 April 12, /archophthalmol.2010 
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